Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study

Prostate

Volumn 75, Issue 13, 2015, Pages 1384-1393

  Kantor, Elizabeth D ^a   Lipworth, Loren ^b   Fowke, Jay H ^b   Giovannucci, Edward L ^a   Mucci, Lorelei A ^a,c   Signorello, Lisa B ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

African Americans; chemoprevention; epidemiologic studies; prostate cancer; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER GRADING; CANCER RISK; CANCER SCREENING; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ETHNIC DIFFERENCE; GLEASON SCORE; HEALTH CARE ACCESS; HEALTH INSURANCE; HUMAN; HYPERCHOLESTEROLEMIA; INCOME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR; AFRICAN AMERICAN; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AFRICAN AMERICANS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84939166073     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23019     Document Type: Article

References (46)

1. Getzenberg RH,. Statins and the risk of prostate cancer or benign prostatic hyperplasia: Biological plausibility. Journal Urol 2010; 184 (2): 415-416.
2. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH,. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106 (12): 1447-1452.
3. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC,. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 2000; 20 (4): 2761-2771.
4. Sassano A, Platanias LC,. Statins in tumor suppression. Cancer Lett 2008; 260 (1-2): 11-19.
5. Zhong WB, Wang CY, Chang TC, Lee WS,. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003; 144 (9): 3852-3859.
6. Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL,. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012; 21 (3): 456-461.
7. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W,. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology 2013; 144 (2): 323-332.
8. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG,. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11 (6): 620-629.
9. Liu Y, Tang W, Wang J, Xie L, Li T, He Y, Deng Y, Peng Q, Li S, Qin X,. Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies. Cancer Causes Control 2014; 25 (2): 237-249.
10. Wu XD, Zeng K, Xue FQ, Chen JH, Chen YQ,. Statins are associated with reduced risk of gastric cancer: A meta-analysis. Eur J Clin Pharmacol 2013; 69 (10): 1855-1860.
11. Khurana V, Bejjanki HR, Caldito G, Owens MW,. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 2007; 131 (5): 1282-1288.
12. Boudreau DM, Yu O, Johnson J,. Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf 2010; 9 (4): 603-621.
13. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG,. Statin use and fatal prostate cancer: A matched case-control study. Cancer 2012; 118 (16): 4046-4052.
14. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, Lieber MM, St Sauver JL,. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 2010; 184 (2): 494-499.
15. Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A,. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010; 127 (7): 1650-1659.
16. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98 (24): 1819-1825.
17. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1): 11-30.
18. Bansal D, Undela K, D'Cruz S, Schifano F,. Statin use and risk of prostate cancer: A meta-analysis of observational studies. PloS ONE 2012; 7 (10): e46691.
19. Kuoppala J, Lamminpaa A, Pukkala E,. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008; 44 (15): 2122-2132.
20. Browning DR, Martin RM,. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 2007; 120 (4): 833-843.
21. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, Smith JA Jr., The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control 2011; 22 (3): 417-426.
22. Hippisley-Cox J, Coupland C,. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. Bmj 2010; 340: 2197.
23. Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS,. Statin use and risk of prostate cancer and high-grade prostate cancer: Results from the REDUCE study. Prostate Cancer Prostatic Dis 2013; 16 (3): 254-259.
24. Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM Jr, Kristal AR,. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol 2014; 192 (2): 379-384.
25. Mucci LA, Stampfer MJ,. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol 2014; 32 (1): 1-2.
26. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC,. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121 (7): 1571-1578.
27. Mondul AM, Caffo B, Platz EA,. Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study. Cancer Epidemiol 2011; 35 (4): e6-11.
28. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA,. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 2010; 21 (5): 671-678.
29. Khosropanah I, Falahatkar S, Farhat B, Heidari Bateni Z, Enshaei A, Allahkhah AA, Khosropanah D,. Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males. Acta Med Iran 2011; 49 (12): 789-794.
30. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM,. Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25 (23): 3462-3468.
31. DeSantis C, Naishadham D, Jemal A,. Cancer statistics for African Americans, 2013. CA Cancer J Clin 2013; 63 (3): 151-166.
32. Marlow NM, Halpern MT, Pavluck AL, Ward EM, Chen AY,. Disparities associated with advanced prostate cancer stage at diagnosis. J Health Care Poor Underserved 2010; 21 (1): 112-131.
33. Signorello LB, Hargreaves MK, Blot WJ,. The Southern Community Cohort Study: Investigating health disparities. J Health Care Poor Underserved 2010; 21 (1 Suppl): 26-37.
34. Signorello LB, Hargreaves MK, Steinwandel MD, Zheng W, Cai Q, Schlundt DG, Buchowski MS, Arnold CW, McLaughlin JK, Blot WJ,. Southern community cohort study: Establishing a cohort to investigate health disparities. J Natl Med Assoc 2005; 97 (7): 972-979.
35. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA,. Gleason score and lethal prostate cancer: Does 3-+-4-=-4-+-3? J Clin Oncol 2009; 27 (21): 3459-3464.
36. Fine J, Gray R,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
37. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL,. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013; 73 (11): 1214-1222.
38. Nielsen SF, Nordestgaard BG, Bojesen SE,. Statin use and reduced cancer-related mortality. N Engl J Med 2013; 368 (6): 576-577.
39. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N,. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31 (25): 3069-3075.
40. Grytli HH, Fagerland MW, Fossa SD, Tasken KA,. Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014; 65 (3): 635-641.
41. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L,. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014; 32 (1): 5-11.
42. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA,. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010; 21 (1): 61-68.
43. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr., Kristal AR,. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009; 18 (11): 2807-2813.
44. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS,. Cholesterol and the risk of grade-specific prostate cancer incidence: Evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer 2012; 12: 25.
45. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr., Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR,. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013; 105 (15): 1132-1141.
46. Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, Wheeler T, Amos CI, von Eschenbach A, Kagan J,. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer 2000; 89 (3): 259-264.